- Exchange: -
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Company Profile for Pharmos Corp (PHA1)
Pharmos Corporation is a bio-pharmaceutical company that discovers and develops new drugs to treat a range of neuroinflammatory disorders. The company has a portfolio of drug candidates under development. Pharmos's main product, dexanabinol, is a synthetic non-psychotropic cannabinoid currently in late stage clinical development for the treatment of traumatic brain injury (TBI).
Key Executives for Pharmos Corp (PHA1)
|Robert F JohnstonChairman||Eric W FangmannActing President/CFO|